Health ConditionsPolycystic ovary syndrome (PCOS) is a female metabolic disorder that centers around three primary concepts: clinical and biological hyperandrogenism (HA), ovulatory dysfunction (OD)—often manifested as irregular menstruation or amenorrhea—and morphological polycystic ovaries (PCO). It is the most common endocrine disorder among reproductive-age women and has lifelong effects on health.
Identified as one of the leading yet treatable causes of infertility, PCOS affects roughly 2% to 40% of women at reproductive age, and more generally between 6% to 13% of women overall, according to most studies. Variation in reported prevalence reflects the diagnostic criteria applied, ethnic background, and methodology used across studies.
The term "PCOS" has been considered "inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma." In 2026, an article in The Lancet described a multi-step global consensus process through which clinicians agreed to rename the condition "polyendocrine metabolic ovarian syndrome" (PMOS). For the purposes of this reference article, the widely established acronym PCOS is retained throughout, as it remains the dominant term in the existing scientific literature.
Three implemented groups of criteria for the diagnosis of PCOS have been in use: from the National Institutes of Health (NIH) in the 1990s, Rotterdam 2003, and the Androgen Excess Polycystic Ovary Syndrome 2009 criteria. Currently, the most widely utilized are the 2003 Rotterdam criteria, which validate the diagnosis with the incidence of two out of three criteria: hyperandrogenism (clinical and/or biochemical), irregular cycles, and polycystic ovary morphology.
The three criteria are: (1) oligo- and/or anovulation; (2) clinical and/or biochemical signs of hyperandrogenism, including acne, hirsutism, and androgenic alopecia; and (3) polycystic ovaries by ultrasound, defined as the presence of 12 or more follicles in each ovary measuring 2–9 mm in diameter and/or ovarian volume greater than 10 ml.
The anti-Müllerian hormone (AMH) in serum is emerging, controversially, as an official polycystic ovarian morphology/PCOS marker that could substitute for the follicular count on ultrasound. In adolescents, the two crucial factors for PCOS diagnosis are hyperandrogenism and irregular cycles, since polycystic ovarian morphology on its own is nonspecific in this age group.
The Rotterdam consensus widened the NIH definition, giving rise to four distinct phenotypes: women with polycystic ovaries, hyperandrogenism, and oligoamenorrhea; women with normal ovaries, hyperandrogenism, and oligoamenorrhea; women with polycystic ovaries and oligoamenorrhea but without hyperandrogenism; and women with polycystic ovaries and hyperandrogenism with normal menses.
Patient presentation is variable, ranging from asymptomatic to having multiple gynecologic, dermatologic, or metabolic manifestations. Clinical manifestations of PCOS are diverse, including menstrual disorders, infertility, obesity, hirsutism, acne, and mood disorders.
The disorder has features that propose a blend of functional reproductive disorders, such as anovulation and hyperandrogenism, and metabolic disorders, such as hyperglycemia, hypertension, and obesity in women.
Patients with PCOS have abnormalities in the metabolism of androgens and estrogen and in the control of androgen production. The major clinical features include menstrual dysfunction, anovulation, and signs of hyperandrogenism. The disrupted hormonal environment, including high levels of androgens, suppresses the growth and development of ovarian follicles. This leads to an accumulation of many small follicles, a feature referred to as polycystic ovarian morphology.
The pathophysiology of PCOS encompasses inherent ovarian dysfunction that is strongly influenced by external factors, such as disturbances of the hypothalamic-pituitary-ovarian axis and hyperinsulinaemia. Exaggerated gonadotrophin-releasing hormone (GnRH) pulsatility results in hypersecretion of luteinising hormone (LH), which has effects both on ovarian androgen production and oocyte development.
Hyperinsulinaemia is secondary both to insulin resistance at the periphery and to abnormal pancreatic beta cell function. In PCOS patients, insulin-sensitive tissues such as liver, skeletal muscle, and fat lose their sensitivity to insulin, while the ovaries remain highly sensitive to insulin. Insulin directly stimulates the production of androgens by cells lining the ovary. Insulin-like growth factor (IGF-1) acts synergistically with luteinising hormone, and hyperinsulinaemia increases the binding site of LH and the androgen response to LH. Insulin resistance independently increases the activity of CYP17A1, an enzyme that produces testosterone and androstenedione.
Metabolic syndrome is twice as common in patients with PCOS compared with the general population, and patients with PCOS are four times more likely than the general population to develop type 2 diabetes mellitus.
PCOS can give rise to several metabolic abnormalities including insulin resistance, type 2 diabetes, and obesity. The syndrome is also linked to a multitude of comorbidities, encompassing cardiovascular diseases, mental disorders, and cancer.
Insulin resistance and hyperinsulinaemia are associated with chronic inflammation, hormonal changes, follicular dysplasia, endometrial receptivity changes, and abortion or infertility. They also increase the incidence of complications during pregnancy and have been associated with anxiety, depression, and other psychological disorders.
Studies have shown that the gut microbiota of PCOS patients is related to the occurrence and development of insulin resistance, hyperandrogenism, chronic inflammation and metabolic syndrome, and may affect the clinical manifestations of PCOS through short-chain fatty acids, lipopolysaccharide, sex hormones and the brain-gut axis. Potential mechanisms by which the gut microbiota may modulate PCOS disease progression include short-chain fatty acids, the gut-brain axis, and the liver-ovary axis.
Three principal characteristics of the pathophysiology of PCOS have been identified: an interaction between reproductive dysfunction and metabolic disorders, high familial aggregation and heritability, and a substantial contribution of environmental factors. PCOS runs in families and a number of genetic abnormalities appear to result in features of the syndrome and account for the heterogeneity of the symptoms. Multi-omic research has uncovered a self-reinforcing network in PCOS: genetic variants in DENND1A predispose to hyperandrogenism and insulin resistance, which in turn modulate gut microbiota composition and bile acid metabolism, fostering systemic inflammation.
Although the pathophysiology of the syndrome is complex and there is no single defect from which it is known to result, it is hypothesized that insulin resistance is a key factor. Insulin resistance is considered the primary pathological basis for PCOS's reproductive dysfunction. Critically, consistent evidence from adult studies demonstrates a clear association between PCOS and an increased risk of metabolic disturbances even in nonobese individuals.
Disruptions in gut microbiota contribute significantly to PCOS by modulating the release of gut-brain peptides and activating inflammatory pathways. Through such mechanisms, gut microbiota dysbiosis is implicated in hyperandrogenism, insulin resistance, chronic inflammation, and metabolic disorders associated with PCOS. Both PCOS and the gut microbiome appear to have some degree of heritability, and these mechanisms may be linked. Hypothetically, the same genetic factors predisposing to PCOS may also promote the establishment of a metabolically adverse gut microbiome, which would further drive the PCOS phenotype.
Women with PCOS frequently display overweight, insulin resistance, and systemic low-grade inflammation. Researchers have hypothesised that endotoxemia resulting from a leaky gut is associated with inflammation, insulin resistance, fat accumulation, and hyperandrogenaemia in PCOS.
Environmental influences, such as nutrition and lifestyle, further influence expression of the syndrome. Further investigation of the environmental factors that are known to drive the development of PCOS through effects after birth, such as the follicular microenvironment and lifestyle, is ongoing.
In PCOS patients, primary bile acids are significantly and positively associated with serum concentrations of total testosterone and androstenedione. Increased circulating conjugated primary bile acids are positively associated with hyperandrogenism in women with PCOS. Furthermore, bile acids have been shown to modulate the function of ovarian cells and are implicated in the pathogenesis of PCOS.
The following section separates, where the literature permits, traditional use (historical, ethnobotanical, or pre-modern usage in defined healing traditions) from scientific evidence (human clinical studies, systematic reviews, and meta-analyses). Evidence strength is characterized explicitly for each entry. A comprehensive review published in Advances in Nutrition noted that specific vitamins (B-12, inositols, folate, vitamins D, E, and K), vitamin-like nutrients (bioflavonoids and α-lipoic acid), minerals (calcium, zinc, selenium, and chromium picolinate), and other formulations (melatonin, omega-3 fatty acids, probiotics, and cinnamon), as well as complementary approaches such as acupuncture and yoga, may be beneficial in PCOS. However, there remain areas of uncertainty and key limitations in the literature that must be overcome before these therapies can be integrated into routine care.
Inositol is a naturally occurring polyol widely distributed in foods including fruits, beans, grains, and nuts. Its use in PCOS is not derived from a formal ethnobotanical tradition; rather, its clinical application emerged from basic science discoveries in the late 20th century regarding its role in insulin signalling, making it a modern nutraceutical rather than a traditional herbal remedy.
Myo-inositol (MI) and D-chiro-inositol (DCI) are involved in a number of biochemical pathways within oocytes, having a role in oocyte maturation, fertilisation, implantation, and post-implantation development. Both inositols have a role in insulin signalling and hormonal synthesis in the ovaries.
A literature search conducted up to September 2020 identified 197 articles on inositols in PCOS, of which 47 were clinical trials including 35 randomised controlled trials (RCTs). Evidence from this body of literature suggests benefits for myo-inositol or D-chiro-inositol for some metabolic measures, and potential benefits from DCI for ovulation, though inositol may have no effect on other outcomes.
A 2024 systematic review and meta-analysis published in The Journal of Clinical Endocrinology & Metabolism, commissioned to inform the 2023 International Evidence-Based PCOS Guidelines, confirmed these findings while noting evidence gaps. Separately, a meta-analysis focused on ART outcomes found that myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25–2.15) and top-grade embryos (RR: 1.12, 95% CI: 1.02–1.23), but was associated with reductions in antral follicle count and anti-Müllerian hormone levels.
Inositol-based treatments should be tailored for specific clinical PCOS phenotypes for which robust evidence has been provided. Future studies are mandatory to ascertain the molecular basis of inositol activity on ovarian cells and to investigate the beneficial effects of appropriate myo-inositol/D-chiro-inositol formulas on larger cohorts of patients. Evidence strength: moderate to strong for metabolic parameters and ART outcomes; evidence for other endpoints remains mixed.
Vitamin D is a fat-soluble secosteroid synthesised endogenously through skin exposure to sunlight, and obtained from dietary sources such as oily fish, egg yolks, and fortified foods. It has no specific historical traditional use in relation to PCOS, as the syndrome was not characterised prior to the 20th century.
In women with PCOS, vitamin D deficiency is common and appears to be multifactorial, reflecting lifestyle factors such as limited sun exposure, higher adiposity, and dietary intake, as well as metabolic factors including insulin resistance. Observational data indicate that 67–85% of women with PCOS have serum 25-hydroxyvitamin D levels below 20 ng/mL, a prevalence higher than that observed in the general population, even after adjustment for BMI.
A systematic review and meta-analysis including 13 RCTs with 824 patients found that serum fasting plasma glucose, fasting insulin, HOMA-IR, and VLDL-cholesterol were significantly decreased in the vitamin D group versus placebo. The vitamin D supplementation group also showed a significantly elevated level of QUICKI (a measure of insulin sensitivity).
However, recent interventional trials investigating the effects of vitamin D supplementation in PCOS have yielded inconsistent results. This may be explained at least in part by differences in study population sizes, study design, study durations ranging from 8 weeks to 6 months, or different dosing regimens such as daily versus weekly versus one-time administration.
Vitamin D influences the balance between androgens and estrogens, which may have a role in pathophysiological mechanisms of PCOS. Evidence strength: moderate for metabolic parameters in women who are deficient; results for hormonal and reproductive outcomes are inconsistent.
Berberine is an isoquinoline alkaloid found in several plants including Berberis vulgaris (barberry), Coptis chinensis (goldthread), and Hydrastis canadensis (goldenseal). In Traditional Chinese Medicine (TCM), berberine-containing plants have been used for millennia to address metabolic and inflammatory conditions, including conditions described as involving "damp-heat" and menstrual irregularity, though these indications were not historically framed in terms of PCOS as currently defined.
A systematic review including 12 RCTs found that berberine had similar live birth rates compared with placebo or metformin, and lower live birth rates compared with letrozole. There was a significant difference between berberine and placebo in terms of decreasing total testosterone (8 RCTs, 577 participants, MD: −0.34, 95% CI: −0.47 to −0.20) and luteinising hormone to follicle-stimulating hormone (LH/FSH) ratio.
Berberine was associated with decreasing total cholesterol (3 RCTs, 201 participants; MD: −0.44), waist circumference (3 RCTs, 197 participants, MD: −2.74 cm), and waist-to-hip ratio compared with metformin, but not with improved BMI. This review found no solid evidence that berberine could improve live birth or other clinical outcomes in women with PCOS.
Berberine, among other herbal agents, has been shown to modulate insulin signalling, androgen synthesis, inflammatory pathways, and oxidative stress, with initial clinical trials reporting improvements in metabolism and hormones to a similar extent as standard therapies in selected populations. Evidence strength: preliminary to moderate for metabolic markers; insufficient to support use for reproductive outcomes.
NAC is not an herb or traditional remedy. It is a stable, acetylated form of the amino acid L-cysteine, developed in the 1960s as a pharmaceutical mucolytic. Its application in PCOS is entirely based on modern clinical observation and does not derive from any traditional healing system.
N-acetylcysteine is an acetylated variant of the L-cysteine amino acid that scavenges reactive oxygen species, and is considered a safe, effective, and economical nutritional supplement. NAC is known to be beneficial in PCOS owing to its antioxidant potential and insulin-sensitising properties.
A meta-analysis of 18 studies involving 2,185 women with PCOS that evaluated the potential impact of NAC on sex hormones and ovulation reported that NAC significantly reduced total testosterone levels and may be positive in improving ovulation.
A separate meta-analysis of 11 RCTs including 869 women with PCOS concluded that NAC is effective in improving metabolic parameters in PCOS and may be a promising nutritional supplement. A meta-analysis of 22 studies (n = 2,515) found that NAC was associated with a statistically significant increase in progesterone (SMD 0.95, 95% CI: 0.13–1.77) and endometrial thickness (SMD 0.58, 95% CI: 0.10–1.06) compared to placebo. Women receiving NAC had higher odds of having a live birth, getting pregnant, and ovulation compared to placebo; however, women with NAC were less likely to achieve pregnancy or ovulation compared to metformin.
Despite its promise, NAC should not be considered a first-line treatment for PCOS. The observed heterogeneity underscores the need for standardised clinical trials with consistent NAC dosages, treatment durations, and participant stratification according to the PCOS phenotype. Evidence strength: preliminary to moderate for metabolic and reproductive outcomes; not a replacement for established pharmacological agents.
Omega-3 fatty acids, particularly EPA and DHA, are found in high concentrations in oily fish and marine algae. Traditional diets in coastal populations (e.g., Mediterranean, Japanese, and Northern European fishing communities) have long emphasized fish consumption, though not in the specific context of PCOS.
Accumulating evidence indicates that omega-3 polyunsaturated fatty acids, among other bioactive compounds, can ameliorate core PCOS manifestations. Omega-3 fatty acid-rich diets are among the dietary interventions that have been found to improve insulin sensitivity and hormonal balance in women with PCOS. Improvements in hyperinsulinaemia, dyslipidaemia, ovulation, and hyperandrogenaemia have been reported with the use of nutraceutical combinations including omega-3 fatty acids. Evidence strength: moderate for metabolic parameters, particularly lipid profiles and insulin sensitivity; evidence for reproductive outcomes is more limited.
Cinnamon (Cinnamomum verum and Cinnamomum cassia) has been used in Ayurvedic, Traditional Chinese Medicine, and Middle Eastern healing systems for thousands of years. Historical uses included addressing digestive complaints, warming the body, and regulating menstruation, though the modern PCOS construct was not available to traditional practitioners.
A review of herbal medicines in PCOS identified Cinnamomum cassia as one of ten herbs with demonstrated mechanisms of reproductive endocrinological effect in PCOS, oligo/amenorrhoea, and hyperandrogenism.
A systematic review of cinnamon and PCOS (searching from database inception to January 2020) retrieved 266 studies and included nine eligible for evaluation. Results showed that increased high-density lipoprotein and insulin sensitivity were achieved by cinnamon supplementation, while LDL, triglyceride, and blood glucose were decreased in patients with PCOS. However, results related to the potential effects of cinnamon on body weight and BMI were inconsistent, calling for further studies. Despite improved results regarding the effect of cinnamon on oxidative stress and ovarian function, further studies are required to explore the precise mechanisms. Evidence strength: preliminary; positive signals for metabolic markers, but trial quality is variable and sample sizes are small.
Vitex agnus-castus (chasteberry) is native to the Mediterranean and Central Asia and has been used in European herbal traditions, particularly in Germany and ancient Greece, to address menstrual irregularities, premenstrual syndrome, and infertility. Historically, it was believed to reduce sexual desire (hence the name "chaste tree") and to regulate female hormonal function. It has been used in modern European phytotherapy, and preparations are available as Commission E-recognised products in Germany for premenstrual complaints.
Clinical equivalence for prolactin-lowering effects of Vitex agnus-castus (40 mg/day) and the pharmaceutical bromocriptine (5 mg/day) was found in one study including 40 women with hyperprolactinaemia. Mean prolactin concentrations following three months of Vitex treatment were significantly reduced (946 to 529 mIU/l, p < 0.001), comparable to the bromocriptine group (885 to 473 mIU/l, p < 0.001). The mean difference in prolactin reduction between the two groups was not significant. Positive effects for Vitex agnus-castus in oligo/amenorrhoea and infertility were demonstrated in three placebo-controlled RCTs.
A 2025 RCT involving 60 women with PCOS assigned to standardised Vitex extract (5.8 mg/day) or placebo for 12 weeks found that Vitex agnus-castus improved oxidative stress markers and insulin resistance and favourably modulated clinical manifestations of PCOS. These findings suggest a clinically meaningful benefit and support further investigation into Vitex as an adjunctive therapy.
Preclinical and clinical studies provide evidence that six herbal medicines may have beneficial effects for women with oligo/amenorrhoea, hyperandrogenism, and PCOS. However, the quantity of preclinical data was limited, and the quality of clinical evidence was variable. Evidence strength: preliminary to moderate; the most consistent signal is for prolactin regulation and menstrual cycle support; effects directly on PCOS metabolic phenotype require more study.
Glycyrrhiza glabra and related species have been used in Traditional Chinese Medicine, Ayurveda, and ancient Greek and Egyptian medicine. In TCM, licorice (Gan Cao) is among the most frequently used herbs, serving as a harmonising agent and used in formulations addressing female reproductive disorders including menstrual irregularity. In Ayurveda, it is used for hormonal imbalances.
Glycyrrhiza spp. was identified among ten herbal medicines with demonstrated mechanisms of reproductive endocrinological effect relevant to PCOS, oligo/amenorrhoea, and hyperandrogenism. Glycyrrhizin, the major active constituent, has been studied for its ability to inhibit 11β-hydroxysteroid dehydrogenase and modulate androgen metabolism, though clinical RCT evidence specific to PCOS remains limited. There is less robust evidence for the complementary combination of spironolactone and Glycyrrhiza spp. for hyperandrogenism. Evidence strength: preliminary, based largely on mechanistic and laboratory data, with limited clinical trial evidence in PCOS specifically.
Cimicifuga racemosa (syn. Actaea racemosa), known as black cohosh, was used by Native American peoples and later adopted into North American and European herbal medicine for female reproductive complaints including menstrual pain, irregularity, and menopausal symptoms. It is the subject of Commission E and ESCOP monographs for menopausal symptoms.
There was evidence for an equivalent effect of Cimicifuga racemosa and the pharmaceutical clomiphene citrate in the context of ovulation induction in PCOS-related studies. A review identified herbal medicines with demonstrated mechanisms of reproductive endocrinological effect, and found evidence for Cimicifuga racemosa having an effect comparable to clomiphene citrate for inducing ovulation. Evidence strength: limited but suggestive; only a small number of trials have been conducted specifically in PCOS populations.
Spearmint has been used in Mediterranean traditional medicine and in Moroccan folk medicine as a tea for conditions including hirsutism, being historically regarded as a plant with cooling and hormone-modulating properties.
Mentha piperita (peppermint) was identified among herbal medicines with demonstrated mechanisms of reproductive endocrinological effect relevant to PCOS. For spearmint specifically, small human trials have examined the plant's anti-androgenic effects. Two RCTs — one published in 2007 in Phytotherapy Research and one in 2009 — found significant reductions in free testosterone and LH in women drinking spearmint tea twice daily for 30 days. The 2009 double-blind RCT (n = 42 women with PCOS) found a significant decrease in free testosterone and increase in LH and FSH compared with placebo tea. These trials are small and the evidence is preliminary, though the anti-androgenic signal is biologically plausible.
Zinc-rich foods (oysters, red meat, legumes, seeds) have been consumed across world cultures, and zinc supplementation has been part of traditional medicine systems in various forms. Its application in PCOS is, however, a modern evidence-based concept.
Zinc is among the minerals for which accumulating evidence indicates the potential to ameliorate core PCOS manifestations. RCTs have reported benefits of supplementing vitamin D with varying mixtures of magnesium, zinc, vitamin K, and vitamin E on hormonal profiles, inflammation, and oxidative stress in women with PCOS. Multiple small RCTs and meta-analyses suggest zinc supplementation may reduce hirsutism scores, lower androgen levels, and improve fasting glucose and HOMA-IR in women with PCOS. The overall evidence base is preliminary, limited by small study populations and heterogeneous dosing protocols.
Chromium has no formal traditional medicinal use predating its modern biochemical identification as a trace element involved in carbohydrate metabolism.
Chromium picolinate is among the minerals identified in a comprehensive review as potentially beneficial in PCOS. Several small RCTs have examined chromium picolinate in PCOS, with outcomes including reductions in fasting insulin, HOMA-IR, and total testosterone, as well as improvements in ovulation. A 2017 meta-analysis found significant reductions in fasting insulin and testosterone levels, though study heterogeneity is substantial and most trials are small. Evidence strength: preliminary.
Selenium is an essential trace mineral with no historical traditional use for PCOS specifically.
Selenium is among the minerals for which accumulating evidence indicates the potential to ameliorate core PCOS manifestations. Small RCTs have evaluated selenium supplementation (typically 200 µg/day) in PCOS, reporting improvements in oxidative stress markers and reductions in insulin resistance. Evidence strength: preliminary; limited to small, short-duration trials.
A systematic review identified the following ten herbal medicines with demonstrated mechanisms of reproductive endocrinological effect in PCOS, oligo/amenorrhoea, and hyperandrogenism: Cimicifuga racemosa, Cinnamomum cassia, Curcuma longa, Glycyrrhiza spp., Matricaria chamomilla, Mentha piperita, Paeonia lactiflora, Silybum marianum, Tribulus terrestris, and Vitex agnus-castus. Additional herbal medicines including green tea, caraway, black mint tea, ginger, fennel, Nigella sativa, and bitter olive have shown significant effects on improving biochemical, hormonal, and symptoms of PCOS in clinical studies. For most of these, the evidence base is preliminary, often resting on small single trials or mechanistic/animal data.
Dietary habits, including caloric intake, macronutrient composition, and the quality of food choices, play a critical role in weight management, insulin sensitivity, and inflammatory markers in women with PCOS. Treatment for PCOS usually initiates with a series of lifestyle modifications such as diet, weight loss, and exercise. Since obesity worsens the clinical presentation of PCOS, weight management is one of the main treatment strategies according to the International Evidence-Based Guideline for the Assessment and Management of PCOS.
A diet low in refined carbohydrates and high in fibre can help to regulate blood sugar levels and improve insulin sensitivity. Previous studies have reported the impact of various dietary patterns, including the consumption of low levels of saturated fat, a low glycaemic index (GI) score, and the consumption of a high-fibre and ketogenic Mediterranean diet on PCOS management. Previous evidence has found that a low glycaemic diet may have benefits for individuals undergoing IVF and natural fertility, and that it reduced body fat and BMI and improved pregnancy outcomes.
The Mediterranean diet is commonly recognised as a health-promoting dietary pattern due to its peculiar features, including the regular consumption of unsaturated fats, low glycaemic index carbohydrates, fibre, vitamins and antioxidants, and moderate amounts of animal-derived proteins.
A 12-week RCT (n = 72 overweight patients with PCOS) comparing a Mediterranean/low-carbohydrate diet to a low-fat diet found that the Mediterranean/low-carbohydrate group had more significant reductions in weight (−6.10 vs −4.79 kg), BMI, waist circumference, waist-to-hip ratio, body fat percentage, total testosterone, and LH/FSH ratio. In addition, fasting insulin and HOMA-IR index decreased significantly in the Mediterranean/low-carbohydrate group compared with the low-fat group.
One of the few RCTs to investigate the benefits of a Mediterranean diet intervention on PCOS features demonstrated that, in women with overweight or obesity, a low-energy Mediterranean-style diet was more effective than a calorie-restricted low-fat diet in reducing body weight, waist circumference, cardiometabolic and hormonal parameters, including fasting blood glucose, insulin sensitivity, blood lipid levels, total testosterone, and LH concentrations. These findings suggest that a Mediterranean diet has the potential to offer a sustainable lifestyle solution for PCOS management.
Dietary interventions such as foods with low glycaemic index scores; caloric restrictions; high-fibre, omega-3 fatty acid-rich diets; ketogenic diets; Mediterranean diets; antioxidant-rich food; and anti-inflammatory diets improve insulin sensitivity and hormonal balance in women with PCOS.
Lifestyle changes are suggested as first-line interventions in managing PCOS. Physical activity, including aerobic and resistance exercise, enhances insulin sensitivity, helps weight loss, and improves metabolic and reproductive outcomes in women with PCOS. Losing weight is one of the most effective measures to regulate the menstrual cycle and improve the symptoms of PCOS.
Stress reduction, physical fitness, and quality of life are among the outcomes achieved with mind-body interventions such as yoga, tai chi, qigong, and mindfulness-based stress reduction. These interventions are noted in the PCOS literature as supportive tools, though the evidence base is primarily from small, uncontrolled or pilot studies.
A number of clinical studies have attempted to use fecal microbiota transplantation, probiotic supplementation, and traditional Chinese medicine to regulate gut microbiota and explore the possibility of treating PCOS-related features. Probiotics have been identified among formulations that may be beneficial in PCOS, though this remains a rapidly evolving and preliminary area of investigation.
The body of nutritional and natural health research in PCOS faces several consistent methodological challenges:
4-Hydroxyisoleucine is the principal bioactive amino acid in fenugreek seeds with documented insulin-secretagogue and insulin-sensitizing activity. It stimulates glucose-dependent insulin secretion from pancreatic beta-cells and has been studied in insulin-resistant states including PCOS.
Alpha-lipoic acid (ALA) is an endogenous antioxidant with insulin-sensitizing properties. It is listed in comprehensive reviews of evidence-based supplements for PCOS, where it has shown reductions in insulin resistance and improvements in metabolic parameters in RCTs.
A small Japanese study (n=7 PCOS women; 15g ACV/day for up to 110 days) found ovulatory function restored in 4 of 7 participants, likely via insulin sensitization. A 2026 RCT (n=94) specifically assessed ACV as adjunct therapy for MetS and insulin resistance in PCOS patients. Evidence base is preliminary but includes human data.
Ashwagandha (Withania somnifera) is an adaptogenic Ayurvedic herb with evidence for modulating cortisol, improving thyroid function, and reducing insulin resistance—all relevant to PCOS. RCTs and systematic reviews include it among herbal interventions studied in PCOS-related metabolic and hormonal dysregulation.
A. racemosus has been investigated for management of letrozole-induced polycystic ovarian syndrome in animal models, with supporting data on hormonal modulation. Its phytoestrogenic and HPG axis modulatory properties are mechanistically relevant to PCOS. Human clinical trial evidence for PCOS specifically is limited.
Multiple human RCTs document astaxanthin's benefits in PCOS: a triple-blind RCT (n=58, 12 mg/day, 8 weeks) found significant reductions in fasting glucose, HOMA-IR, LDL-C, oxidative stress markers and increased HDL-C and antioxidant capacity. A 2026 systematic review further confirmed improvements in ovarian granulosa cell function and metabolic parameters in PCOS patients.
A systematic review of 12 RCTs found berberine (from Berberis species including barberry) more efficacious than metformin for improving insulin resistance, dyslipidemia, and reducing androgen levels and LH/FSH ratio in PCOS. Multiple studies show reductions in testosterone and FAI, increases in SHBG, and improvement in clinical symptoms including hirsutism and acne.
Berberine, an alkaloid from plants such as Coptis chinensis and Berberis, has been evaluated in multiple RCTs for PCOS. It activates AMPK similarly to metformin, improving insulin sensitivity, reducing fasting insulin, lowering testosterone, and supporting menstrual regularity in women with PCOS-associated insulin resistance.
Bifidobacterium bifidum is one of the probiotic strains included in multi-strain probiotic RCTs demonstrating improvements in PCOS metabolic, inflammatory, and hormonal parameters. It is among the Bifidobacterium strains cited in comprehensive PCOS probiotic evidence reviews.
Bifidobacterium breve is specifically listed as one of the Bifidobacterium strains used in probiotic RCTs for PCOS in major systematic reviews. Probiotic regimens including this strain have shown improvements in metabolic and hormonal markers in PCOS.
Bifidobacterium longum is one of the Bifidobacterium strains explicitly included in RCTs of probiotic supplementation for PCOS. These trials have shown improvements in metabolic, hormonal, and inflammatory parameters in PCOS women.
Black seed (Nigella sativa) has been studied in RCTs for PCOS, with evidence for reductions in testosterone, LH, BMI, and improvements in menstrual regularity. It is listed in multiple systematic herbal medicine reviews for PCOS including a comprehensive 2023 PMC review.
C. crista has been specifically studied in animal PCOS models. A 2023 study (Cureus, PMC9957572) showed that high-dose C. crista (500 mg/kg) significantly increased ovum count and decreased atretic follicles in letrozole-induced PCOS rats compared to disease controls. Ayurvedic use as an ovulation inducer supports this application.
Vitex is recognized as a hypothalamic-pituitary-ovarian (HPO) regulator relevant to PCOS, with a published pharmacological rationale review and supportive preclinical and limited clinical data. A 12-week RCT in 70 women found VAC comparable to combined oral contraceptives for normalizing the menstrual cycle and reducing DHEAS. Hyperprolactinemia and progesterone insufficiency in PCOS represent specific targets for VAC.
Several RCTs and meta-analyses have examined chromium supplementation in women with PCOS, given the central role of insulin resistance in this condition. A systematic review of five RCTs found chromium significantly lowered a measure of insulin resistance and one trial showed improved beta-cell function, though effects on fasting insulin and insulin sensitivity per se were not significant. Overall evidence is mixed and of uncertain clinical relevance.
Chromium, particularly as chromium picolinate, has been evaluated in multiple RCTs for PCOS. Network meta-analyses confirm chromium reduces fasting insulin and improves HOMA-IR in PCOS women. A 2025 systematic review and meta-analysis confirmed chromium has a clear therapeutic benefit in reducing oxidative stress, dyslipidemia, and glucose metabolic disorders in PCOS.
Cinnamon (particularly Cinnamomum cassia) is one of the most studied herbal medicines for PCOS metabolic features. Multiple RCTs and a comprehensive herbal medicine review found cinnamon improves insulin sensitivity and menstrual cyclicity in PCOS. It is listed among evidence-supported complementary therapies in major PCOS supplement reviews.
Coptis chinensis (goldthread) is the primary botanical source of berberine, which has the most robust clinical evidence for PCOS among herbal alkaloids. Coptis itself is used in traditional Chinese medicine for conditions overlapping with PCOS, and berberine-containing Coptis preparations are active components in PCOS management.
CoQ10 is an endogenous antioxidant that has been shown effective for PCOS women undergoing assisted reproductive technologies, reducing insulin resistance, increasing FSH, and improving blood lipids. A meta-analysis confirmed CoQ10 reduces fasting plasma glucose and HOMA-IR and improves sex hormone levels in PCOS.
Curcumin, the main polyphenol from turmeric, has been evaluated in multiple RCTs in PCOS, with a 2022 meta-analysis of 5 RCTs confirming significant reductions in BMI, fasting glucose, insulin, HOMA-IR, and total cholesterol. It reduces hyperandrogenism and oxidative stress via anti-inflammatory mechanisms.
D-Pinitol is a methylated inositol with insulin-mimetic properties. It shares mechanisms with D-chiro-inositol, improving insulin signaling in ovarian tissue. It has been studied in PCOS for insulin resistance and androgen reduction, with preclinical and early clinical evidence supporting its use.
Daidzein is the second major soy isoflavone with documented phytoestrogenic, anti-androgenic, and insulin-sensitizing properties. It is precursor to equol (a potent anti-androgen) in gut-metabolizing individuals. Studies suggest benefits for androgen excess, insulin resistance, and SHBG in PCOS.
EGCG, the major bioactive catechin from green tea, has insulin-sensitizing, anti-inflammatory, and anti-androgenic properties relevant to PCOS. It activates AMPK, reduces oxidative stress, and has shown improvements in fasting insulin, BMI, and androgen levels in PCOS-related studies.
Multiple RCTs and meta-analyses demonstrate that EPA/DHA omega-3 supplementation improves dyslipidemia, reduces serum triglycerides, and modulates androgen profiles in women with PCOS. EPA-containing omega-3s have also been associated with improved menstrual regularity and clinical pregnancy rates in PCOS patients undergoing ovulation induction.
EPO has been evaluated in polycystic ovary syndrome (PCOS) in clinical studies. A 2024 systematic review found EPO 'was effective in PCOS' in a few studies but cautioned evidence levels are low and decisive claims cannot be made without larger trials. Proposed mechanisms involve GLA effects on hormonal balance, insulin sensitivity, and inflammation.
Fennel has been clinically trialed for PCOS in a small double-blind RCT showing no significant effect on ovarian cyst symptoms, and in combination studies. Animal studies demonstrate beneficial renal and hormonal effects in PCOS models. Evidence remains preliminary.
Fenugreek (Trigonella foenum-graecum) has been studied in multiple RCTs and included in systematic herbal medicine reviews for PCOS, showing effects on menstrual regularity, androgen reduction, and metabolic parameters. Traditional use in Ayurveda for female hormonal disorders spans centuries.
In letrozole-induced PCOS rat models, fisetin normalized glucose, lipid, hormone profiles (testosterone, estradiol, progesterone), insulin resistance, and ovarian SIRT1/AMPK expression, with efficacy comparable to metformin. No human PCOS trials exist.
Multiple clinical trials and meta-analyses support omega-3 supplementation from fish oil for women with polycystic ovary syndrome (PCOS). Fish oil has been shown to reduce androgen levels, improve menstrual frequency, lower triglycerides, and reduce insulin resistance—all key PCOS features. The ConsumerLab Fish Oil Review notes a recent study showing fish oil may improve pregnancy rates in PCOS-related infertility.
Flaxseed is rich in dietary fiber, phytoestrogens (lignans), and alpha-linolenic acid (ALA). Reviews confirm flaxseed has potential to improve metabolic, anthropometric, and hormonal parameters in PCOS. Clinical evidence includes improvements in insulin resistance and androgen levels.
Folic acid supplementation has been studied in PCOS, showing reductions in BMI particularly in patients with elevated homocysteine levels. It is included among evidence-based vitamins recommended in major PCOS supplement reviews, and elevated homocysteine—reduced by folate—is a recognized cardiovascular risk factor in PCOS.
Formononetin is a phytoestrogenic isoflavone found primarily in red clover and some legumes. It is a precursor to daidzein and has anti-androgenic, anti-inflammatory, and insulin-sensitizing properties documented in preclinical PCOS models and emerging clinical evidence.
Genistein is the primary isoflavone in soy with documented insulin-sensitizing, anti-androgenic, and ovarian-protective properties in PCOS models. Clinical evidence shows it improves androgen levels, SHBG, and insulin resistance parameters in women with PCOS when used at physiological doses.
Ginger (Zingiber officinale) has been studied in PCOS through RCTs, showing anti-inflammatory, antioxidant, and insulin-sensitizing properties. A systematic herbal review for PCOS identified ginger among evaluated herbal medicines, and clinical studies show improvements in androgen levels and metabolic markers.
Glucomannan (konjac fiber) is a water-soluble dietary fiber that reduces postprandial glucose, insulin, and cholesterol. Multiple clinical trials confirm its insulin-sensitizing effects relevant to PCOS. Systematic reviews of PCOS supplements include dietary fiber interventions showing metabolic benefits.
Green tea and its catechins (especially EGCG) have been studied for PCOS, appearing in systematic herbal medicine reviews for PCOS with documented mechanisms. A systematic review listed green tea among herbal medicines with positive outcomes for PCOS-related infertility and metabolic irregularities.
Gymnemic acids are the principal bioactive triterpenoid saponins from Gymnema sylvestre responsible for its blood sugar-lowering effects. They reduce glucose absorption, stimulate insulin secretion, and have been studied for insulin resistance—the core metabolic defect in PCOS. Clinical trials in insulin-resistant states support their use.
Myo-inositol (MI) and D-chiro-inositol (DCI) are among the most extensively studied nutraceuticals for PCOS, supported by over 35 RCTs. They act as insulin-sensitizing second messengers in ovarian cells, improving insulin resistance, reducing androgens, restoring ovulation, and improving oocyte quality. The 40:1 MI:DCI ratio is considered optimal.
Isoflavones (from soy, red clover, and other legumes) have phytoestrogenic and anti-androgenic properties directly relevant to PCOS. Multiple systematic reviews and RCTs confirm isoflavone supplementation improves androgen levels, SHBG, and insulin resistance in PCOS women.
L-carnitine has demonstrated consistent benefits for PCOS in network meta-analyses and RCTs, primarily reducing BMI and body weight, and outperforming other supplements for this outcome. It improves lipid metabolism, insulin sensitivity, and has shown improvements in ovarian response in some trials.
NAC has been specifically evaluated in PCOS in multiple RCTs, improving ovulation, pregnancy rates, and insulin resistance in clomiphene-resistant patients. A double-blind RCT of 150 women with PCOS found NAC added to clomiphene significantly increased ovulation and pregnancy rates. NAC's dual action on oxidative stress and insulin sensitization makes it particularly relevant to PCOS pathophysiology.
Lactobacillus acidophilus is the most commonly included strain in probiotic RCTs for PCOS. Probiotic supplementation including this strain has been shown to improve metabolic, inflammatory, and hormonal parameters and improve fertility in PCOS in multiple RCTs and meta-analyses.
Lactobacillus casei is among the Lactobacillus strains explicitly listed in major systematic reviews as a constituent of evidence-based probiotic regimens studied in PCOS RCTs, which have shown improvements in metabolic, hormonal, and inflammatory parameters.
Lactobacillus rhamnosus is one of the Lactobacillus strains explicitly included in multi-strain probiotic RCTs for PCOS showing improved metabolic and hormonal outcomes. It is listed in the Advances in Nutrition 2022 review as a constituent of evidence-supported probiotic regimens in PCOS.
Licorice root (Glycyrrhiza species) has demonstrated androgen-lowering effects in clinical trials for PCOS-related hyperandrogenism. It is one of the six herbal medicines identified in a comprehensive herbal medicine review for PCOS with both mechanistic and corroborating clinical evidence.
Magnesium deficiency is common in PCOS and linked to insulin resistance. RCTs show magnesium oxide supplementation (250mg/day) reduced fasting insulin, HOMA-IR, total cholesterol, LDL, and fasting blood glucose in PCOS. When co-supplemented with zinc, calcium, and vitamin D, it significantly improved hirsutism scores, inflammation, and oxidative stress.
A published randomized open trial in 80 PCOS patients found maitake SX-fraction induced ovulation in 76.9% of women over 12 weeks, nearly comparable to clomiphene citrate. Combination therapy rescued ovulation in 75% of clomiphene/maitake non-responders. The mechanism involves maitake's insulin-sensitizing effect reducing ovarian androgen excess.
A double-blind RCT (n=25 women) found marjoram tea taken twice daily for one month significantly reduced DHEA-S and fasting insulin vs. placebo, and improved insulin sensitivity markers. Multiple subsequent animal studies have corroborated hormonal and metabolic improvements.
Melatonin has been evaluated in multiple RCTs for PCOS, showing improvements in oocyte quality, pregnancy rates in IUI, reduced testosterone, and anti-oxidant benefits. It is listed in major evidence reviews as one of the evidence-supported formulations for PCOS.
Milk thistle (Silybum marianum) and its active component silymarin have demonstrated mechanisms relevant to PCOS, including lowering testosterone, increasing SHBG synthesis, inhibiting inflammation, and reducing blood glucose. It is identified in herbal medicine reviews as having documented reproductive endocrinological mechanisms in PCOS.
NAC is an acetylated derivative of L-cysteine with potent antioxidant properties. Multiple RCTs and meta-analyses show NAC improves ovulation rates, pregnancy rates, and reduces testosterone and insulin resistance in women with PCOS. One meta-analysis of 18 studies (2,185 women) found significant testosterone reduction and improved reproductive function.
Omega-3 fatty acids (EPA and DHA) have been evaluated in multiple RCTs in PCOS women, demonstrating reductions in fasting blood glucose, triglycerides, LDL, and improvements in insulin sensitivity. A 2023 network meta-analysis found omega-3 was superior to placebo for reducing fasting blood glucose (SUCRA 93.53%) in PCOS.
Paeonia lactiflora (white peony) is one of the herbal medicines identified in a comprehensive herbal medicine review for PCOS with both demonstrated mechanisms and corroborating clinical evidence for reducing androgen levels and restoring ovulatory function, particularly when used in the traditional combination formula Shakuyaku-kanzo-to.
Phytoestrogens as a class—including isoflavones, lignans, and coumestans—modulate sex hormone signaling and SHBG levels relevant to PCOS. Multiple systematic reviews include phytoestrogenic compounds among evidence-based interventions for PCOS-related androgen excess and metabolic dysfunction.
A 2025 systematic review and meta-analysis of RCTs found pomegranate juice significantly reduced testosterone and hs-CRP while increasing HDL in women with PCOS. An earlier RCT demonstrated improvements in cardiovascular risk factors in PCOS women with concentrated pomegranate juice. Pomegranate's anti-androgenic and anti-inflammatory effects are the proposed mechanisms.
Women with PCOS have anovulatory cycles producing chronic progesterone deficiency with unopposed estrogen, leading to irregular cycles, heavy periods, and elevated endometrial cancer risk. Cyclic progesterone therapy restores cycle regularity, reduces androgen-related symptoms, and protects the endometrium. A 6-month pilot RCT demonstrated significant improvements in fluid retention, cycle length, and cycle regularity.
Quercetin is a polyphenol flavonoid with anti-androgenic, anti-inflammatory, and insulin-sensitizing properties studied in PCOS. Preclinical studies show it reduces testosterone, restores ovarian function, and upregulates CYP19a1 (aromatase). Clinical evidence is emerging from RCTs showing improvements in androgen and metabolic parameters.
Red clover (Trifolium pratense) is rich in isoflavones (formononetin, biochanin A, daidzein, genistein) with anti-androgenic and phytoestrogenic properties. Preliminary clinical evidence and systematic reviews support its use for androgen reduction and hormonal balance in PCOS.
Resveratrol, a polyphenol found in grapes and berries, has been studied in multiple RCTs for PCOS. Clinical trials demonstrated reductions in total testosterone, DHEA-S, and fasting insulin at doses of 1,000–1,500mg/day, along with improved menstrual regularity and insulin sensitivity.
A 2015 human study found RJ (1,000 mg/day, 8 weeks) improved testosterone and menstrual regularity in PCOS women. A published animal study found 200 mg/kg RJ normalized reproductive hormones, restored estrus cycles, and improved ovarian histology in a testosterone-induced PCOS rat model. A 2025 immunological review specifically addressed RJ in PCOS management.
Saffron (Crocus sativus) and its active components crocin and safranal have been studied in PCOS for their anti-inflammatory, antioxidant, and insulin-sensitizing properties. RCTs in PCOS women have shown improvements in metabolic markers, hormonal profiles, and psychological symptoms including depression and anxiety that frequently accompany PCOS.
Selenium supplementation has been studied in multiple RCTs for PCOS, showing reductions in testosterone, hirsutism, CRP, and oxidative stress markers. A 2023 systematic review and meta-analysis of RCTs confirmed selenium's effects in PCOS. It is listed among evidence-supported minerals in major PCOS supplement reviews.
Soy isoflavones have mechanistic and emerging clinical evidence in PCOS, improving androgen excess, insulin resistance, ovarian morphology, and oxidative stress in animal models. Human studies suggest beneficial effects on hormonal and metabolic parameters, though large RCTs are still needed.
Soy isoflavones (genistein, daidzein) have phytoestrogenic and insulin-sensitizing properties studied in PCOS. Systematic reviews list soy isoflavones among nutritional supplements with evidence in PCOS, showing improvements in androgen levels, SHBG, insulin resistance, and lipid profiles.
Spearmint leaf has two RCTs demonstrating significant anti-androgenic effects in PCOS women, with reductions in free and total testosterone and improvements in LH/FSH ratios. It is one of few herbal teas with randomized trial data specifically in PCOS-related hyperandrogenism.
Streptococcus thermophilus is listed alongside Lactobacillus and Bifidobacterium strains in evidence-based multi-strain probiotic preparations for PCOS. RCTs using these preparations showed improvements in metabolic and hormonal parameters in PCOS women.
Thymoquinone is the primary bioactive compound of black seed (Nigella sativa) with anti-inflammatory, antioxidant, and insulin-sensitizing properties. Preclinical PCOS models show it reduces ovarian cysts, normalizes hormone profiles, and improves insulin resistance. Clinical evidence through black seed oil RCTs in PCOS is emerging.
Trans-pterostilbene is a dimethylated analog of resveratrol with higher bioavailability, sharing its insulin-sensitizing, anti-inflammatory, and anti-androgenic mechanisms. While direct PCOS-specific RCTs are limited, its superior pharmacokinetics and shared mechanisms with clinically-validated resveratrol support its relevance in PCOS.
A limited number of clinical trials and multiple animal studies suggest tribulus can support follicular development, reduce polycystic ovarian features, and improve anovulatory infertility in PCOS. The PMC literature confirms clinical trial evidence but notes it is restricted to few studies.
Tribulus terrestris has pre-clinical and clinical evidence for ovulation induction, menstrual regularity, and FSH elevation in women with PCOS or anovulatory infertility. Two animal RCTs and clinical trials support its ability to promote ovulation. It is listed among herbal medicines with demonstrated reproductive endocrinological mechanisms for PCOS.
Curcumin has been evaluated for PCOS in RCTs with evidence suggesting benefit for insulin resistance, androgen levels, and inflammatory markers. A ClinicalTrials.gov-registered RCT (N=120) is actively evaluating curcumin for metabolic control, microbiota, and quality of life in PCOS. Literature is inconclusive but mechanistically and clinically supported.
Clinical studies show CoQ10 supplementation can improve multiple PCOS-related parameters, including FSH levels, testosterone, insulin resistance (HOMA-IR), and lipid profiles. A Frontiers review (2025) found CoQ10 impedes PCOS progression and enhances fertility. Mechanistically, CoQ10 reduces ovarian oxidative stress and supports mitochondrial function in granulosa cells.
Vitamin B12 is listed among specific vitamins with evidence of benefit for PCOS in major systematic reviews. B12 deficiency is common in PCOS women, particularly those taking metformin, and is associated with elevated homocysteine and impaired metabolic function.
Vitamin B6 (pyridoxine) is a cofactor in steroid hormone metabolism and neurotransmitter synthesis. Deficiency has been associated with elevated androgens and impaired hormone clearance. Major PCOS supplement reviews include vitamin B complex (including B6) among evidence-relevant nutrients for PCOS management.
Biotin (vitamin B7) plays a role in carboxylation reactions central to fatty acid synthesis and gluconeogenesis. Studies show biotin supplementation improves glucose metabolism and insulin sensitivity. In PCOS, where insulin resistance is central, biotin's metabolic effects and its role in improving androgenic alopecia (a common PCOS feature) are clinically relevant.
Folate (vitamin B9) is among the specific vitamins listed in major PCOS supplement systematic reviews as having evidence of benefit. It reduces elevated homocysteine—a recognized cardiovascular risk factor in PCOS—and may reduce BMI in PCOS women with high homocysteine levels.
Methylfolate (5-MTHF) is the bioavailable form of folate that bypasses the MTHFR conversion step. Given the high prevalence of MTHFR polymorphisms in PCOS-associated populations and folate's role in homocysteine reduction and reproductive health, methylfolate is specifically relevant for PCOS women with impaired folate metabolism.
Vitamin D deficiency is highly prevalent in PCOS and associated with insulin resistance, menstrual irregularity, and metabolic dysfunction. Multiple RCTs and systematic reviews show vitamin D supplementation improves hormonal profiles, inflammation, and oxidative stress markers in PCOS, particularly when combined with calcium or other micronutrients.
Vitex agnus-castus (chaste tree) is supported by multiple RCTs for PCOS-related menstrual irregularity, infertility, and hyperprolactinemia. A 2025 RCT (60 PCOS women, 12 weeks) showed significant improvements in oxidative stress markers, insulin resistance, and clinical features. Clinical equivalence with bromocriptine for prolactin lowering has been demonstrated.
Women with PCOS frequently have zinc deficiency, which correlates with insulin resistance severity. Multiple RCTs show zinc supplementation (4–50mg/day for 8–12 weeks) improves HOMA-IR, lipid profiles, and androgen markers. Systematic reviews confirm benefits when used alone or in combination with other micronutrients.
PCOS involves androgen excess and insulin resistance; DIM's ability to modulate androgen and estrogen metabolism provides a theoretical basis for its use. No published RCT has specifically evaluated DIM in a PCOS population. Use is supported by mechanistic reasoning and clinical extrapolation from hormonal studies.
Dong quai (Angelica sinensis) has been used for over 2,000 years in traditional Chinese medicine as the foremost female tonic herb for menstrual irregularity, amenorrhoea, and gynecological complaints—conditions central to PCOS. Scientific evidence is preliminary, but it is among the most historically documented herbs for female reproductive disorders.
Gymnema sylvestre is the plant from which gymnemic acids are derived. Used in Ayurvedic medicine for millennia for blood sugar regulation, its insulin-sensitizing properties have preclinical and early clinical support relevant to PCOS-associated insulin resistance and metabolic dysfunction.
Gymnema sylvestre is an Ayurvedic herb used for millennia for blood sugar regulation. Gymnemic acids reduce glucose absorption and stimulate insulin secretion. Given that insulin resistance is a core PCOS feature, Gymnema has traditional and preliminary scientific rationale for use in PCOS, though dedicated PCOS RCTs are limited.
T. cordifolia has traditional use for menstrual and hormonal conditions in Ayurveda. Preclinical animal model evidence (letrozole-induced PCOS in mice) shows TC oil preparation reversed PCOS-related morphological and metabolic effects. A PMC review (PMC10221073) identifies TC's role in managing insulin resistance and lipid/carbohydrate metabolism associated with PCOS. No human clinical trials for PCOS are available.
Maca (Lepidium meyenii) is a Peruvian root traditionally used for fertility, hormonal balance, and menstrual regulation in Andean cultures. Preliminary scientific evidence suggests it may improve hormonal profiles, fertility, and FSH/LH balance, relevant to PCOS, though dedicated PCOS RCTs are limited.
Momordica charantia has documented traditional use for menstrual irregularities and reproductive abnormalities relevant to PCOS. A preclinical animal study evaluated it in a letrozole-induced PCOS rat model. No human clinical trials have been conducted for PCOS specifically.
Saw palmetto (Serenoa repens) is traditionally used and has emerging evidence as a 5-alpha-reductase inhibitor, reducing DHT conversion from testosterone. This anti-androgenic mechanism is directly relevant to PCOS hirsutism and androgenic alopecia, and it is included in complementary PCOS treatment discussions.
Go back